These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29702126)

  • 1. Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway.
    Cheng YZ; Yang SL; Wang JY; Ye M; Zhuo XY; Wang LT; Chen H; Zhang H; Yang L
    Life Sci; 2018 Jul; 205():184-192. PubMed ID: 29702126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Pharmacol Res; 2010 Jan; 61(1):34-9. PubMed ID: 19635564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.
    Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
    Pharmacol Res; 2012 Mar; 65(3):297-302. PubMed ID: 22100460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of receptors of advanced glycation end products ameliorates diabetic osteogenesis of adipose-derived stem cells through DNA methylation and Wnt signalling pathway.
    Zhang M; Li Y; Rao P; Huang K; Luo D; Cai X; Xiao J
    Cell Prolif; 2018 Oct; 51(5):e12471. PubMed ID: 30014569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoking prevents bone loss and enhances osteoblastic bone formation by modulating the AGEs/IGF-1/β-catenin/OPG pathway in type 2 diabetic db/db mice.
    Yang Y; Li R; Wang P; Zhao Y; Li J; Jiao J; Zheng H
    Cell Biol Int; 2024 Oct; 48(10):1507-1519. PubMed ID: 38937979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end products inhibit the osteogenic differentiation potential of adipose-derived stem cells by modulating Wnt/β-catenin signalling pathway via DNA methylation.
    Li Y; Wang L; Zhang M; Huang K; Yao Z; Rao P; Cai X; Xiao J
    Cell Prolif; 2020 Jun; 53(6):e12834. PubMed ID: 32468637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products.
    Liu CJ; Yang X; Wang SH; Wu XT; Mao Y; Shi JW; Fan YB; Sun LW
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.
    Yamagishi S
    Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morroniside attenuates high glucose-induced BMSC dysfunction by regulating the Glo1/AGE/RAGE axis.
    Sun Y; Zhu Y; Liu X; Chai Y; Xu J
    Cell Prolif; 2020 Aug; 53(8):e12866. PubMed ID: 32643284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways.
    Abo El-Nasr NME; Saleh DO; Mahmoud SS; Nofal SM; Abdelsalam RM; Safar MM; El-Abhar HS
    Eur J Pharmacol; 2020 May; 874():173010. PubMed ID: 32067934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells.
    Matsui T; Nishino Y; Maeda S; Takeuchi M; Yamagishi S
    Microvasc Res; 2011 May; 81(3):269-73. PubMed ID: 21236267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
    Kusunoki H; Taniyama Y; Rakugi H; Morishita R
    J Am Heart Assoc; 2013 Apr; 2(2):e000103. PubMed ID: 23608606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice].
    Ye XL; Huang WC; Zheng YT; Liang Y; Gong WQ; Yang CM; Liu B
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):505-511. PubMed ID: 28446404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation.
    Zhang H; Chu Y; Zheng H; Wang J; Song B; Sun Y
    Aging (Albany NY); 2020 Nov; 13(1):525-536. PubMed ID: 33298623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gliclazide alters macrophages polarization state in diabetic atherosclerosis in vitro via blocking AGE-RAGE/TLR4-reactive oxygen species-activated NF-kβ nexus.
    Jahan H; Choudhary MI
    Eur J Pharmacol; 2021 Mar; 894():173874. PubMed ID: 33460615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
    Rabbani N; Adaikalakoteswari A; Rossing K; Rossing P; Tarnow L; Parving HH; Thornalley PJ
    Amino Acids; 2012 May; 42(5):1627-39. PubMed ID: 21384133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of catalpol on diabetes mellitus-induced male reproductive damage via suppression of the AGEs/RAGE/Nox4 signaling pathway.
    Jiao N; Chen Y; Zhu Y; Wang W; Liu M; Ding W; Lv G; Lu J; Yu B; Xu H
    Life Sci; 2020 Sep; 256():116736. PubMed ID: 31398417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-Influenced Receptors of Advanced Glycation End Product Overexpression Associated With Osteogenic Differentiation Impairment in Patients With Type 2 Diabetes.
    Phimphilai M; Pothacharoen P; Kongtawelert P
    Front Endocrinol (Lausanne); 2021; 12():726182. PubMed ID: 34512554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylglyoxal - an advanced glycation end products (AGEs) precursor - Inhibits differentiation of human MSC-derived osteoblasts in vitro independently of receptor for AGEs (RAGE).
    Waqas K; Muller M; Koedam M; El Kadi Y; Zillikens MC; van der Eerden BCJ
    Bone; 2022 Nov; 164():116526. PubMed ID: 35995334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.